Page 119 - Heca News Today

Novartis said on Monday its canakinumab drug had failed in another trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.

The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.

Bausch Health Companies Inc and Clearside Biomedical Inc said on Monday they received approval from the U.S. health regulator for their eye injection, giving patients access to a novel treatment for vision loss resulting from an inflammatory eye condition.

The United States has administered 413,645,478 doses of COVID-19 vaccines in the country as of Sunday morning and distributed 503,493,015 doses, the U.S. Centers for Disease Control and Prevention said.

Britain reported 45,066 new COVID-19 cases on Thursday and 157 more deaths within 28 days of a positive test, official data showed.

Airbus has rebuffed calls by aircraft leasing companies to temper plans to almost double production of its best-selling A320 jet family, telling them its ambitions are justified by expectations for post-pandemic demand, industry sources said.

The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

The European Union's drug regulator on Monday said it has concluded in its review that Moderna's COVID-19 booster vaccine may be given to people aged 18 years and above, at least six months after the second dose.

Indonesia is "finalising" a deal with Merck & Co to procure its experimental antiviral pills, named molnupiravir, to treat COVID-19 ailments, its health minister said on Monday.

Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry's push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.